SPOTLIGHT -
Dr. Villaruz on Updates From the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC
Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer.
Read More
Dr. Villaruz on Selecting Between Single-Agent and Combination Immunotherapy in NSCLC
Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.
Dr. Villaruz on EGFR-Targeted Therapies in NSCLC
Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses EGFR-targeted therapies in non–small cell lung cancer.
Dr. Villaruz Discusses PD-L1 Expression in Lung Cancer
Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses PD-L1 expression in lung cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)